Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine

Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine

Abstract In the phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine conducted in the U.S., Chile, and Peru, anti-spike binding IgG concentration (spike IgG) and pseudovirus 50% neutralizing antibody titer (nAb ID50) measured four weeks after two doses were assessed as correlates of risk and prote...

Full description

Bibliographic Details
Main Authors: David Benkeser, Youyi Fong, Holly E. Janes, Elizabeth J. Kelly, Ian Hirsch, Stephanie Sproule, Ann Marie Stanley, Jill Maaske, Tonya Villafana, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Flora Castellino, Victor Ayala, Christos J. Petropoulos, Andrew Leith, Deanne Haugaard, Bill Webb, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Lars W. P. van der Laan, Nima S. Hejazi, Lindsay N. Carpp, April K. Randhawa, Michele P. Andrasik, James G. Kublin, Margaret Brewinski Isaacs, Mamodikoe Makhene, Tina Tong, Merlin L. Robb, Lawrence Corey, Kathleen M. Neuzil, Dean Follmann, Corey Hoffman, Ann R. Falsey, Magdalena Sobieszczyk, Richard A. Koup, Ruben O. Donis, Peter B. Gilbert, on behalf of the AstraZeneca AZD1222 Clinical Study Group, the Immune Assays Team, the United States Government (USG)/CoVPN Biostatistics Team
Format: Article
Language:English
Published: Nature Portfolio 2023-03-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-023-00630-0

Internet

https://doi.org/10.1038/s41541-023-00630-0

Similar Items